Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on Imlifidase and Drug Combination for Treating Severe Goodpasture Disease in Patients

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a rare condition known as Goodpasture disease, which is also referred to as anti-GBM antibody disease. This disease affects the kidneys and lungs, causing them to become inflamed and damaged. The trial aims to compare the effectiveness of a new treatment called imlifidase in combination with standard treatments, against standard treatments alone. The standard treatments include medications such as cyclophosphamide, prednisolone, methylprednisolone, trimethoprim, sulfamethoxazole, and loratadine. These medications are used to suppress the immune system, reduce inflammation, and prevent infections.

The purpose of the study is to determine if the combination of imlifidase and standard treatments can improve kidney function more effectively than standard treatments alone. Participants in the study will receive either the combination treatment or the standard treatment. The study will monitor the participants' kidney function over a period of time to assess the effectiveness of the treatments. The trial will also look at other factors such as the time it takes for the disease-causing antibodies to reach non-toxic levels and the overall health status of the participants.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to track the progress of their kidney function. The study will last for several months, and participants will undergo regular check-ups and tests to evaluate their response to the treatment. The results of this trial could provide valuable insights into better treatment options for individuals suffering from Goodpasture disease.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization

    Upon joining the study, you will be randomly assigned to one of two groups. One group will receive the medication imlifidase along with standard care, while the other group will receive standard care alone. This process is random to ensure fairness and accuracy in the study results.

  2. Step 2

    Initial treatment

    If you are in the group receiving imlifidase, you will be given this medication through an intravenous infusion. This means the medication will be delivered directly into your bloodstream through a vein. The dosage is 11 mg, and it will be administered as a single dose at the start of the treatment.

  3. Step 3

    Standard care

    All participants will receive standard care, which includes medications such as methylprednisolone and prednisolone. These are steroids that help reduce inflammation. Methylprednisolone is given as an intravenous infusion, while prednisolone is taken orally. The specific dosage and frequency will be determined by the study doctors based on your individual needs.

    You may also receive other medications like trimethoprim and sulfamethoxazole orally to prevent infections, and loratadine orally to manage any allergic reactions.

  4. Step 4

    Monitoring and follow-up

    Throughout the study, your kidney function will be closely monitored. This includes regular blood tests to measure your estimated glomerular filtration rate (eGFR), which indicates how well your kidneys are working.

    You will have follow-up visits at 3 months and 6 months to assess your kidney function and overall health. During these visits, the study team will check for any side effects and ensure that the treatment is working as intended.

  5. Step 5

    End of study

    At the end of the study, which lasts for approximately 6 months, a final assessment will be conducted. This will include a comprehensive evaluation of your kidney function and any other health parameters that were monitored during the study.

    The results will help determine the effectiveness of imlifidase in combination with standard care compared to standard care alone in treating severe anti-GBM antibody disease.

Who can join the trial?

5 criteria

  • The patient must have a level of anti-GBM antibodies that is above a toxic level. These are specific proteins in the blood that can attack the kidneys.
  • The patient must have haematuria, which means blood in the urine, detectable by a urine test.
  • The patient must have an eGFR (estimated Glomerular Filtration Rate) of less than 20 mL/min/1.73 m². This is a measure of how well the kidneys are working.
  • The patient must be aged 18 years or older.
  • The patient must be willing and able to give written Informed Consent, which means they understand the study and agree to participate, and must be able to follow the study requirements.

Who cannot join the trial?

10 criteria

  • Patients with a history of severe allergic reactions to the study medication.
  • Patients who are currently pregnant or breastfeeding.
  • Patients with any other serious medical condition that might interfere with the study.
  • Patients who have participated in another clinical trial within the last 30 days.
  • Patients with a history of drug or alcohol abuse.
  • Patients who are unable to follow the study procedures or instructions.
  • Patients with a known infection that could affect the study results.
  • Patients who have received an organ transplant.
  • Patients with a history of cancer within the last 5 years, except for certain skin cancers.
  • Patients with uncontrolled high blood pressure.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Imlifidase

    is a medication being tested in this clinical trial for its potential to help people with a severe condition called anti-GBM antibody disease, also known as Goodpasture disease. This disease can cause serious damage to the kidneys. Imlifidase works by breaking down certain antibodies in the body that are responsible for attacking the kidneys. By doing this, it may help to protect the kidneys and improve their function.

  • Standard-of-Care (SoC)

    refers to the usual treatment that patients with Goodpasture disease receive. This can include a combination of medications and therapies that doctors typically use to manage the disease and its symptoms. The goal of standard-of-care is to control the disease and prevent further damage to the kidneys. In this trial, the standard-of-care is being compared to see if adding imlifidase provides better results for patients.

What is already known about the treatment

Imlifidase – Imlifidase is administered through an intravenous infusion, meaning it is delivered directly into the bloodstream via a vein. It is currently being studied in clinical trials for its effectiveness in treating severe anti-GBM antibody disease, also known as Goodpasture disease. This medication works by breaking down specific antibodies in the body that are involved in the disease process, potentially protecting kidney function. Imlifidase is classified as an enzyme-based therapy, which means it uses proteins to target and modify biological processes.

Investigated diseases

Anti-GBM antibody disease (Goodpasture disease) – This is an autoimmune disorder where the immune system mistakenly attacks the basement membrane in the lungs and kidneys. The disease often begins with respiratory symptoms such as coughing and shortness of breath, followed by kidney-related symptoms like blood in the urine and swelling. As the disease progresses, it can lead to inflammation and damage in the kidneys, potentially causing kidney failure. The presence of anti-GBM antibodies in the blood is a hallmark of this condition, leading to the destruction of kidney and lung tissues. Over time, the damage to these organs can become severe, affecting their ability to function properly. The disease requires careful monitoring to manage its progression and impact on the body.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-500121-33-01Protocol code21-HMedIdeS-24Estimated enrolment50 patientsSponsorHansa Biopharma AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.